EATG » Hepatitis

Hepatitis

New WHO guidelines for hepatitis B virus vaccine

The World Health Organization (WHO) issued updated recommendations for the use of the hepatitis B virus (HBV) vaccine, including a WHO report containing excerpts of the new recommendations that was…

HBV surface antibody reduces risk for reactivation during chemotherapy

In a recent meta-analysis of patients with resolved hepatitis B who underwent chemotherapy for hematological malignancies, the presence of positive antibodies to HBV surface antigen, or anti-HBs, was correlated with…

AAP recommends newborn hepatitis B vaccine by 24 hours of age

New recommendations from the American Academy of Pediatrics (AAP) say medically stable newborns weighing 2000 g or more should receive their first dose of the hepatitis B vaccine within the…

Shorter anti-HCV regimen effective in patients with or without cirrhosis

An eight-week regimen containing grazoprevir-ruzasvir-uprifosbuvir appears to be effective for treating hepatitis C virus (HCV) infection in patients with or without cirrhosis, according to findings from a pair of randomized…

Liver fibrosis speeds up around the menopause in women with HIV and HCV co-infection

Menopause is associated with accelerated liver fibrosis in women with HIV and hepatitis C virus (HCV) co-infection, investigators from the United States report in the online edition of Clinical Infectious…

Sharing injection paraphernalia does not lead to HCV transmission

New findings suggest that sharing paraphernalia used to cook and prepare injection drugs does not directly lead to transmission of hepatitis C virus. According to Robert Heimer, PhD, professor of…

Low-level hepatitis B viral load raises liver cancer risk

Low but detectable HBV DNA during antiviral therapy is associated with detrimental long-term outcomes. Having even a low level of hepatitis B virus (HBV) while on treatment with Baraclude (entecavir)…

Men on PrEP & HIV-positive men are getting hepatitis C during sex—here’s why

Hepatitis C is best known as an infection transmitted by blood, with most new cases of hepatitis C caused by sharing injection drug use equipment. But this dangerous infection, which…

Health Canada approves Vosevi and Maviret for the treatment of hepatitis C

Gilead Sciences Canada's press release for the approval of Vosevi is available here. AbbVie Canada's press release for the approval of Maviret is available here.

Medivir licenses exclusive rights to MIV-802 for Greater China to Ascletis

Stockholm, Sweden and Hangzhou, China, 18 August 2017 — Medivir AB and Ascletis today announce that Ascletis has licensed the exclusive rights to develop, manufacture and commercialize Medivir’s nucleotide polymerase…